Efficacy and Tolerability of Methylprednisolone Pulse Therapy in Childhood Epilepsies Other Than Infantile Spasms

Abstract

This retrospective study included 54 children with epilepsy. The treatment consisted of four pulses with single doses of 20 mg/kg/d methylprednisolone (MPR), administered every week on 3 consecutive days. After this initial phase, the intervals between the pulses were increased based on individual factors. MPR pulses were administered exclusively orally in 39 patients and 7.8% of all pulses were applied intravenously. After four pulses, 30 of 54 (56%) patients were responders, according to several clinical and electroencephalography criteria. A response was obtained in 12 of 20 (60%) cases with genetic, 7 of 17 (41%) with structural metabolic, and 11 of 17 (65%) with unknown etiology. Responder rates were 11 of 15 (73%) in patients with continuous spike–waves in slow sleep (CSWS) or Landau–Kleffner syndrome, 2 of 6 in patients with myoclonic astatic epilepsy or Lennox–Gastaut syndrome, and 17 of 31 (55%) in patients with unclassified epilepsies. A response was not correlated with any epilepsy-related clinical factor. The patients received a median of eight MPR pulses (range, 1–52), and the median duration of the therapy was 11 weeks. The response was maintained in 19 of 30 (63%) patients, and 3 of 24 (13%) without initial response became seizure-free (total responder rate at the end of the therapy 22/54 [41%]). The majority of patients experienced adverse effects that were typically mild and transient.

Keywords

pharmacoresistant - epileptic encephalopathy - electroclinical syndrome - corticosteroids

• References

• 1 Wirrell EC, Wong-Kisiel LC-L, Mandrekar J, Nickels KC. What predicts enduring intractability in children who appear medically intractable in the first 2 years after diagnosis?. Epilepsia 2013; 54 (6) 1056-1064
• 2 Snead III OC, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology 1983; 33 (8) 966-970
• 3 Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7 (1) 31-40
• 4 Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev 2008; 4 (4) CD001770
• 5 Lux AL, Edwards SW, Hancock E , et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004; 364 (9447) 1773-1778
• 6 Haberlandt E, Weger C, Sigl SB , et al. Adrenocorticotropic hormone versus pulsatile dexamethasone in the treatment of infantile epilepsy syndromes. Pediatr Neurol 2010; 42 (1) 21-27
• 7 Mytinger JR, Quigg M, Taft WC, Buck ML, Rust RS. Outcomes in treatment of infantile spasms with pulse methylprednisolone. J Child Neurol 2010; 25 (8) 948-953
• 8 Yamamoto H, Asoh M, Murakami H, Kamiyama N, Ohta C. Liposteroid (dexamethasone palmitate) therapy for West syndrome: a comparative study with ACTH therapy. Pediatr Neurol 1998; 18 (5) 415-419
• 9 Gayatri NA, Ferrie CD, Cross H. Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms. Cochrane Database Syst Rev 2007; 1 (1) CD005222
• 10 Buzatu M, Bulteau C, Altuzarra C, Dulac O, Van Bogaert P. Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep. Epilepsia 2009; 50 (Suppl. 07) 68-72
• 11 Sinclair DB, Snyder TJ. Corticosteroids for the treatment of Landau-kleffner syndrome and continuous spike-wave discharge during sleep. Pediatr Neurol 2005; 32 (5) 300-306
• 12 Kilaru S, Bergqvist AGC. Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia. Epilepsia 2007; 48 (9) 1703-1707
• 13 You SJ, Jung DE, Kim HD, Lee HS, Kang H-C. Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy. Eur J Paediatr Neurol 2008; 12 (4) 314-320
• 14 Heyman E, Lahat E, Gandelman-Marton R. Interictal encephalography can influence patient selection for methylprednisolone therapy in pediatric refractory epilepsy. J Child Neurol 2012; 27 (2) 162-167
• 15 Sevilla-Castillo RA, Palacios GC, Ramirez-Campos J, Mora-Puga M, Diaz-Bustos R. Methylprednisolone for the treatment of children with refractory epilepsy. Neuropediatrics 2009; 40 (6) 265-268
• 16 Tsuru T, Mori M, Mizuguchi M, Momoi MY. Effects of high-dose intravenous corticosteroid therapy in Landau-Kleffner syndrome. Pediatr Neurol 2000; 22 (2) 145-147
• 17 Lichtenfeld R, Heyman E, Gandelman-Marton R, Livne A, Lahat E. Intravenous methylprednisolone pulse therapy in a young girl with intractable absence seizures. Isr Med Assoc J 2010; 12 (3) 181-182
• 18 Sofue A, Naiki M, Yokotsuka T , et al. Effect of corticosteroids in a twin child with idiopathic localization-related epilepsy. Brain Dev 2008; 30 (3) 211-214
• 19 Forrest KML, Young H, Dale RC, Gill DS. Benefit of corticosteroid therapy in Angelman syndrome. J Child Neurol 2009; 24 (8) 952-958
• 20 Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998; 51 (2) 529-534
• 21 Yeh EA, Weinstock-Guttman B. The management of pediatric multiple sclerosis. J Child Neurol 2012; 27 (11) 1384-1393
• 22 Aghighi Y, Attarod L, Javanmard M. Efficacy of methylprednisolone pulse therapy in children with rheumatoid arthritis. Clin Rheumatol 2008; 27 (11) 1371-1375
• 23 Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004; 50 (11) 3408-3417